Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2040

Annual patent cliff calendar for 2040 — US pharmaceutical patents by expiration date.

Patents
1,866

Quick answer

1,866 indexed pharmaceutical patents have expiration dates in 2040. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 10626145

    Peptide with anti-obesity and anti-diabetes activity and use thereof

    CAREGEN CO., LTD. · Granted Tue Apr 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10626469

    Rapid identification of microorganisms

    BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE OF THE UNIVERSITY OF NEVADA, RENO · Granted Tue Apr 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10624850

    Emulsion formulations of an NK-1 receptor antagonist and uses thereof

    Heron Therapeutics, Inc. · Granted Tue Apr 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10626399

    Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3)

    United States Government as represented by the Department of Veterans Affairs · Granted Tue Apr 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10627409

    Therapeutic antibodies against ROR-1 protein and methods for use of same

    The Regents of the University of California · Granted Tue Apr 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10626146

    α4β7 thioether peptide dimer antagonists

    Protagonist Therapeutics, Inc. · Granted Tue Apr 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10626094

    Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Tue Apr 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10624887

    Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14,-diol

    Relmada Therapeutics, Inc. · Granted Tue Apr 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10626129

    Heteroaryl inhibitors of PDE4

    Tetra Discovery Partners · Granted Tue Apr 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. CA 3116885

    COMPOSITIONS ET METHODES D'ADMINISTRATION DE TRANSGENE

    CRISPR THERAPEUTICS AG [CH] · Granted Thu Apr 23 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Apr 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10632091

    Dosage forms and therapeutic uses of L-4-chlorokynurenine

    VISTAGEN THERAPUETICS, INC. · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10633351

    Halogenated compound and axially chiral isomer thereof

    Medshine Discovery Inc. · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10632185

    Chimeric west nile/zika viruses and methods of use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10633363

    EPAC1 activators as HIV latency reversal agents (LRA)

    The Board of Regents of the University of Texas System · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10632101

    Methods and compositions for supporting endogenous systems related to life span

    USANA Health Sciences, Inc. · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10632251

    Device, system and methods for the oral delivery of therapeutic compounds

    Rani Therapeutics, LLC · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10633447

    Soluble engineered monomeric Fc

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10632088

    Inactivators of Toxoplasma gondii ornithine aminotransferase for treating toxoplasmosis and malaria

    Northwestern University · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10632072

    Systems and methods for continuous manufacturing of liposomal drug formulations

    UNIVERSITY OF CONNECTICUT · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10631559

    Acidic extracts and beverages containing 2,5-piperazinedione,3,6-bis(phenylmethyl)-(3S,6S)-

    SUNTORY BEVERAGE & FOOD ASIA PTE. LTD. · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10632070

    Hydrogel toxin-absorbing or binding nanoparticles

    The Regents of the University of California · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10632255

    Drug infusion device

    MILESTONE SCIENTIFIC, INC. · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10633493

    Facile assembly of soft nanoarchitectures and co-loading of hydrophilic and hydrophobic molecules via flash nanoprecipitation

    Northwestern University · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10632152

    Chimeric antigen receptor and methods of use thereof

    The Regents of the University of California · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10632180

    Methods and compositions for improved cognition

    The Regents of the University of California · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10633386

    BET protein degraders

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10632092

    Composition for and method to increase serum adiponectin and reduce body fat

    FIRST FRUITS BUSINESS MINISTRY, LLC · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10632198

    Pharmaceutical composition comprising brinzolamide

    SENTISS PHARMA PRIVATE LIMITED · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10633411

    Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway

    The Board of Regents of the University of Texas System · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10633345

    Human plasma kallikrein inhibitors

    BioCryst Pharmaceuticals, Inc. · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10632211

    Demethylation to treat eye disease

    The Regents of the University of California · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10633344

    Multiple-component solid phases containing at least one active pharmaceutical ingredient

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10633381

    KRas G12C inhibitors

    Mirati Therapeutics, Inc. · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10633434

    Anti-C5 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10633654

    Modified RNAi polynucleotides and uses thereof

    Phio Pharmaceuticals Corp. · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10633657

    Methods for treatment of polycystic kidney disease

    The Board of Regents of the University of Texas System · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10633451

    Bispecific antibody molecules with antigen-transfected T-cells and their use in medicine

    Ludwig-Maximilians-Universitat Munchen · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10633445

    T-cell receptor (TCR)-binding antibodies and uses thereof

    The Board of Regents of the University of Texas System · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10633370

    Phenyl indole allosteric inhibitors of p97 ATPase

    The Regents of the University of California · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10633432

    VC-CAR molecule and use thereof in removing HIV-1 infected cells

    Shenzhen City of Regeneration Biological Pharmaceutical Technology Co., Ltd. · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10632184

    Compositions and methods for stabilizing alphaviruses with improved formulations

    Takeda Vaccines, Inc. · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10632209

    ASH1L inhibitors and methods of treatment therewith

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10632194

    Anti-ErbB3 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10632114

    Pyruvate kinase activators for use in therapy

    Agios Pharmaceuticals, Inc. · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10632173

    Formulations and methods of use for alpha connexin C-terminal (ACT) peptides

    FIRSTRING RESEARCH, INC. · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10632199

    Long-acting polymeric delivery systems

    Heron Therapeutics, Inc. · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10633442

    Antibodies to connexin 43 (Cx43) hemichannels and methods of use thereof to inhibit Cx43 hemichannel opening

    The Board of Regents of the University of Texas System · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10633632

    Human disc tissue

    DiscGenics, Inc. · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2040?

1,866 published patents in our USPTO index have expiration dates falling in calendar year 2040.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.